Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

详细信息    查看全文

• 作者：Lisa Pleyer^a ; Ulrich Germing^b ; Wolfgang R. Sperr^c ; Werner Linkesch^d ; Sonja Burgstaller^e ; Reinhard Stauder^f ; Michael Girschikofsky^g ; Martin Schreder^h ; Michael Pfeilstockerⁱ ; Alois Lang^j ; Thamer Sliwa^k ; Dietmar Geissler^l ; Konstantin Schlick^a ; Gudrun Placher-Sorko^a ; Georg Theiler^d ; Josef Thaler^e ; Martina Mitrovic^f ; Daniel Neureiter^m ; Peter Valent^c ; Richard Greil^a ; ^{r.greil@salk.at" class="auth_mail}
• 关键词：Matched-pair analysis ; CMML ; Chronic myelomonocytic leukemia ; Azacitidine ; Austrian Azacitidine Registry
• 刊名：Leukemia Research
• 出版年：April, 2014
• 年：2014
• 卷：38
• 期：4
• 页码：475-483
• 全文大小：684 K

文摘

Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p = 0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p = 0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.